Boston Partners
PRTK

Boston Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Boston Partners’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-112,143
Closed -$1.09M – 754
2018
Q3 		$1.09M Sell
112,143
-3,139
-3% -$31.7K ﹤0.01% 666
2018
Q2 		$1.18M Sell
115,282
-18,400
-14% -$208K ﹤0.01% 723
2018
Q1 		$1.74M Hold
133,682
– – ﹤0.01% 664
2017
Q4 		$2.39M Hold
133,682
– – ﹤0.01% 649
2017
Q3 		$3.35M Hold
133,682
– – ﹤0.01% 585
2017
Q2 		$3.22M Sell
133,682
-23,176
-15% -$512K ﹤0.01% 577
2017
Q1 		$3.02M Hold
156,858
– – ﹤0.01% 594
2016
Q4 		$2.42M Buy
+156,858
New +$2.04M ﹤0.01% 650

Other funds holding PRTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $190M AUM 50.42% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Boston Partners's PRTK Position: Q4 2018 in Review

Boston Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2018, closing a stake of 112,143 shares — an estimated $1.09M sold.

Boston Partners first reported a position in PRTK in Q4 2016 and held it in 8 quarters. The position peaked at $3.35M in Q3 2017. 102 funds tracked by Wall St. Rank hold PRTK as of Q4 2018.

  • Boston Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Boston Partners sold 112,143 Paratek Pharmaceuticals, Inc. shares in Q4 2018, an estimated $1.09M.
  • Boston Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2016 and held it in 8 quarters.
  • Boston Partners's Paratek Pharmaceuticals, Inc. position peaked at $3.35M in Q3 2017.
  • 102 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2018.

Based on Boston Partners's 13F filing for Q4 2018, filed 7 Feb 2019.